Current Problems in Cancer
Volume 30, Issue 3 , Pages 107-158 , May 2006

Hodgkin’s Lymphoma

  • Richard W. Tsang (Associate Professor)

      Affiliations

    • Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to Richard Tsang, MD, FRCPC, Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G2M9.
    • ,
  • David C. Hodgson (Assistant Professor)

      Affiliations

    • Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    • ,
  • Michael Crump (Associate Professor)

      Affiliations

    • Department of Hemtology and Medical Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada

References 

  1. American Cancer Society. Cancer facts and figures, 2006. Available from: http://www.cancer.org/docroot/stt/stt0.asp.
  2. Miller TP , LeBlanc M , Braziel RM , Grogan TM , Press OW , Fisher RI . Was the bimodal age incidence of Hoddgkin’s Lymphoma a result of mistaken diagnoses of non-Hodgkin’s Lymphoma? . Blood . 2002;100:771a
  3. Hjalgrim H , Askling J , Rostgaard K , Hamilton-Dutoit S , Frisch M , Zhang JS , et al.   Characteristics of Hodgkin’s lymphoma after infectious mononucleosis . N Engl J Med . 2003;349:1324–1332
  4. Lukes RJ , Butler JJ . The pathology and nomenclature of Hodgkin’s disease . Cancer Res . 1966;26:1063–1083
  5. In:  Jaffe ES ,  Harris NL ,  Stein H ,  Vardiman JW editor. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissues . Lyon, France: IARC Press; 2001;
  6. Howell SJ , Grey M , Chang J , Morgenstern GR , Cowan RA , Deakin DP , et al.   The value of bone marrow examination in the staging of Hodgkin’s lymphoma (a review of 955 cases seen in a regional cancer centre) . Br J Haematol . 2002;119:408–411
  7. Vinnicombe SJ , Reznek RH . Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma . Eur J Nucl Med Mol Imaging . 2003;30(suppl 1):S42–S55
  8. Greene FL , Page DL , Fleming ID , Fritz AG , Balch CM , Haller DG , et al.   AJCC Cancer Staging Manual . 6th Edition. New York, NY: Springer-Verlag; 2002;
  9. Lister TA , Crowther D , Sutcliffe SB , Glatstein E , Canellos GP , Young RC , et al.   Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease (Cotswolds meeting) . J Clin Oncol . 1989;7:1630–1636
  10. Wirth A , Seymour JF , Hicks RJ , Ware R , Fisher R , Prince M , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma . Am J Med . 2002;112:262–268
  11. Van Den Bossche B , Lambert B , De Winter F , Kolindou A , Dierckx RA , Noens L , et al.   18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients . Nucl Med Commun . 2002;23:1079–1083
  12. Friedberg JW , Fischman A , Neuberg D , Kim H , Takvorian T , Ng AK , et al.   FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma (a blinded comparison) . Leuk Lymphoma . 2004;45:85–92
  13. Feinstein AR , Sosin DM , Wells CK . The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer . N Engl J Med . 1985;312:1604–1608
  14. UICC-International Union Against Cancer . TNM Classification of Malignant Tumours . 6th Edition. New York, NY: Wiley-Liss; 2002;
  15. Carbone PP , Kaplan HS , Musshoff K , Smithers DW , Tubiana M . Report of the Committee on Hodgkin’s Disease staging classification . Cancer Res . 1971;31:1860–1861
  16. Kaplan HS , Rosenberg SA . The treatment of Hodgkin’s disease . Med Clin North Am . 1966;50:1591–1610
  17. Specht L . Prognostic factors in Hodgkin’s disease . Cancer Treat Rev . 1991;18:21–53
  18. Hasenclever D , Diehl V . A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease . N Engl J Med . 1998;339:1506–1514
  19. Diehl V , Sextro M , Franklin J , Hansmann ML , Harris N , Jaffe E , et al.   Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease (report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease) . J Clin Oncol . 1999;17:776–783
  20. Schlembach PJ , Wilder RB , Jones D , Ha CS , Fayad LE , Younes A , et al.   Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease . Cancer J . 2002;8:377–383
  21. Crennan E , D’Costa I , Liew KH , Thompson J , Laidlaw C , Cooper I , et al.   Lymphocyte predominant Hodgkin’s disease (a clinicopathologic comparative study of histologic and immunophenotypic subtypes) . Int J Radiat Oncol Biol Phys . 1995;31:333–337
  22. Duhmke E , Franklin J , Pfreundschuh M , Sehlen S , Willich N , Ruhl U , et al.   Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease (long-term results of a randomized trial of radiotherapy alone) . J Clin Oncol . 2001;19:2905–2914
  23. Engert A , Schiller P , Josting A , Herrmann R , Koch P , Sieber M , et al.   Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma (results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group) . J Clin Oncol . 2003;21:3601–3608
  24. Pappa VI , Norton AJ , Gupta RK , Wilson AM , Rohatiner AZ , Lister TA , et al.   Nodular type of lymphocyte predominant Hodgkin’s disease. A clinical study of 50 cases . Ann Oncol . 1995;6:559–565
  25. Wilder RB , Schlembach PJ , Jones D , Chronowski GM , Ha CS , Younes A , et al.   European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease . Cancer . 2002;94:1731–1738
  26. Nogova L , Reineke T , Eich HT , Josting A , Muller-Hermelink HK , Wingbermuhle K , et al.   Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma (a retrospective analysis from the German Hodgkin Study Group (GHSG)) . Ann Oncol . 2005;16:1683–1687
  27. Wirth A , Yuen K , Barton M , Roos D , Gogna K , Pratt G , et al.   Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma . Cancer . 2005;104:1221–1229
  28. Ekstrand BC , Lucas JB , Horwitz SM , Fan Z , Breslin S , Hoppe RT , et al.   Rituximab in lymphocyte-predominant Hodgkin disease (results of a phase 2 trial) . Blood . 2003;101:4285–4289
  29. Peters MV . Prophylactic treatment of adjacent areas in Hodgkin’s disease . Cancer Res . 1966;26:1232–1243
  30. Vijayakumar S , Myrianthopoulos LC . An updated dose-response analysis in Hodgkin’s disease . Radiother Oncol . 1992;24:1–13
  31. Loeffler M , Diehl V , Pfreundschuh M , Ruhl U , Hasenclever D , Nisters-Backes H , et al.   Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease . J Clin Oncol . 1997;15:2275–2287
  32. Yahalom J . Transformation in the use of radiation therapy of Hodgkin lymphoma (new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT)) . Eur J Haematol . 2005;(Suppl):90–97
  33. Eich H , Mueller R , Engert A , Hanseman K , Skripnitchenko R , Pfistner B , et al.   Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin’s Lymphoma (Interim analysis of the German Hodgkin Study Group Trial HD10) . Int J Radiat Oncol Biol Phys . 2005;63(suppl 1):S1
  34. Koontz BF , Kirkpatrick JP , Clough RW , Prosnitz RG , Gockerman JP , Moore JO , et al.   Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin’s disease (cure balanced against complications) . J Clin Oncol . 2006;24:605–611
  35. Eich HT , Staar S , Gossmann A , Hansemann K , Skripnitchenko R , Kocher M , et al.   Centralized radiation oncologic review of cross-sectional imaging of Hodgkin’s disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group . Int J Radiat Oncol Biol Phys . 2004;58:1121–1127
  36. Gospodarowicz MK , Sutcliffe SB , Clark RM , Dembo AJ , Fitzpatrick PJ , Munro AJ , et al.   Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone . Int J Radiat Oncol Biol Phys . 1992;22:859–865
  37. Hoskin PJ , Smith P , Maughan TS , Gilson D , Vernon D , Syndikus I , et al.   Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma . Clin Oncol (R Coll Radiol) . 2005;17:47–53
  38. Ng AK , Bernardo MP , Weller E , Backstrand KH , Silver B , Marcus KC , et al.   Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger . J Clin Oncol . 2002;20:2101–2108
  39. Wirth A , Chao M , Corry J , Laidlaw C , Yuen K , Ryan G , et al.   Mantle irradiation alone for clinical stage I-II Hodgkin’s disease (long-term follow-up and analysis of prognostic factors in 261 patients) . J Clin Oncol . 1999;17:230–240
  40. Backstrand KH , Ng AK , Takvorian RW , Jones EL , Fisher DC , Molnar-Griffin BJ , et al.   Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin’s disease . J Clin Oncol . 2001;19:736–741
  41. Liao Z , Ha CS , Vlachaki MT , Hagemeister F , Cabanillas F , Hess M , et al.   Mantle irradiation alone for pathologic stage I and II Hodgkin’s disease (long-term follow-up and patterns of failure) . Int J Radiat Oncol Biol Phys . 2001;50:971–977
  42. Specht L , Gray RG , Clarke MJ , Peto R  International Hodgkin’s Disease Collaborative Group . Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease (a meta-analysis of 23 randomized trials involving 3,888 patients) . J Clin Oncol . 1998;16:830–843
  43. Ruffer JU , Ballova V , Glossmann J , Sieber M , Franklin J , Nogova L , et al.   BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease (results of the German Hodgkin Study Group) . Leuk Lymphoma . 2005;46:1561–1567
  44. Press OW , LeBlanc M , Lichter AS , Grogan TM , Unger JM , Wasserman TH , et al.   Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease . J Clin Oncol . 2001;19:4238–4244
  45. Specht L . Very long-term follow-up of the Danish National Hodgkin Study Group’s randomized trial of radiotherapy (RT) alone vs. combined modality treatment (CMT) for early stage Hodgkin Lymphoma, with special reference to second tumours and overall survival . Blood . 2003;102:2351
  46. Meerwaldt JH , et al.   Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favourable supradiagpragmatic clinical stages I-II Hodgkin’s lymphoma (preliminary results of the EORTC-GELA H8-F randomized trial (#20931) in 543 patients) . Leuk Lymphoma . 2001;42:12
  47. Bonadonna G , Bonfante V , Viviani S , Di Russo A , Villani F , Valagussa P , et al.   ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease (long-term results) . J Clin Oncol . 2004;22:2835–2841
  48. Klasa RJ , Connors JM , Gascoyne RD , Hoskins P , Shenkier T , Voss N . Brief Chemotherapy (CT) with involved field (IFRT) or extended field (EFRT) radiation after clinical staging (CS) are equivalent and both superior to EFRT alone following laparotomy staging (PS IA, IIA) in limited Hodgkin’s lymphoma (HL) . Leuk Lymphoma . 2001;42(S2):51; Abstract p-087
  49. Radford JA , Williams MV , Hancock BW , Hoskin P , Sun-Mynt H , Smith P , et al.   Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mnatle field RT for clinical IA/IIA supra-diaphragmatic Hodgkin’s disease (HD) . Eur J Haematol . 2004;73(suppl 65):39
  50. Tsang RW , Gospodarowicz MK , O’Sullivan B . Staging and management of localized non-Hodgkin’s lymphomas (variations among experts in radiation oncology) . Int J Radiat Oncol Biol Phys . 2002;52:643–651
  51. Shakespeare TP , Holecek MJ . Defining involved field (IF) radiotherapy in Hodgkin’s disease . Australas Radiol . 1998;42:172
  52. Horning SJ , Hoppe RT , Breslin S , Bartlett NL , Brown BW , Rosenberg SA . Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease (mature results of a prospective clinical trial) . J Clin Oncol . 2002;20:630–637
  53. Raemaekers J , Kluin-Nelemans H , Teodorovic I , Meerwaldt C , Noordijk E , Thomas J , et al.   The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer . Eur J Cancer . 2002;38(suppl 4):S107–S113
  54. Canellos GP , Anderson JR , Propert KJ , Nissen N , Cooper MR , Henderson ES , et al.   Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD . N Engl J Med . 1992;327:1478–1484
  55. Duggan DB , Petroni GR , Johnson JL , Glick JH , Fisher RI , Connors JM , et al.   Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease (report of an intergroup trial) . J Clin Oncol . 2003;21:607–614
  56. Longo DL . Radiation therapy in Hodgkin disease (why risk a Pyrrhic victory?) . J Natl Cancer Inst . 2005;97:1394–1395
  57. Canellos GP . Chemotherapy alone for early Hodgkin’s lymphoma (an emerging option) . J Clin Oncol . 2005;23:4574–4576
  58. Longo DL , Glatstein E , Duffey PL , Young RC , Hubbard SM , Urba WJ , et al.   Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease (seven-year results of a prospective randomized trial) . J Clin Oncol . 1991;9:906–917
  59. Biti GP , Cimino G , Cartoni C , Magrini SM , Anselmo AP , Enrici RM , et al.   Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease (eight-year update of an Italian prospective randomized study) . J Clin Oncol . 1992;10:378–382
  60. Pavlovsky S , Maschio M , Santarelli MT , Muriel FS , Corrado C , Garcia I , et al.   Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease . J Natl Cancer Inst . 1988;80:1466–1473
  61. Nachman JB , Sposto R , Herzog P , Gilcrest GS , Wooden SL , Thomson J , et al.   Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy . J Clin Oncol . 2002;20:3765–3771
  62. Meyer RM , Gospodarowicz MK , Connors JM , Pearcey RG , Bezjak A , Wells WA , et al.   Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma (National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group) . J Clin Oncol . 2005;23:4634–4642
  63. Straus DJ , Portlock CS , Qin J , Myers J , Zelenetz AD , Moskowitz C , et al.   Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease . Blood . 2004;104:3483–3489
  64. Cosset JM , Henry-Amar M , Pellar-Cosset B , Carde P , Girinski T , Tubiana M , et al.   Pericarditis and myocardial infarction after Hodgkin’s disease therapy . Int J Radiat Oncol Biol Phys . 1991;21:447–449
  65. Cosset JM , Ferme C , Eghbali H , et al.   MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin’s lymphoma (preliminary results of the EORTC-GELA H8-U randomized trial (# 20931) in 995 patients) . Leuk Lymphoma . 2001;42:12
  66. Diehl V , Brillant C , Engert A , Wolf J , Nogova L , Mueller RP , et al.   Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin’s lymphoma (results of the fourth interim analysis of the HD 11 trial of the GHSG) . Eur J Haematol . 2004;73(suppl 65):37
  67. Gobbi PG , Levis A , Chisesi T , Broglia C , Vitolo U , Stelitano C , et al.   ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma (final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi) . J Clin Oncol . 2005;23:9198–9207
  68. Canellos GP , Niedzwiecki D . Long-term follow-up of Hodgkin’s disease trial . N Engl J Med . 2002;346:1417–1418
  69. Connors JM , Klimo P , Adams G , Burns BF , Cooper I , Meyer RM , et al.   Treatment of advanced Hodgkin’s disease with chemotherapy–comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD (a report from the National Cancer Institute of Canada clinical trials group) . J Clin Oncol . 1997;15:1638–1645
  70. Hancock BW , Gregory WM , Cullen MH , Hudson GV , Burton A , Selby P , et al.   ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin’s disease (results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial) . Br J Cancer . 2001;84:1293–1300
  71. Johnson PW , Radford JA , Cullen MH , Sydes MR , Walewski J , Jack AS , et al.   Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma (results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)) . J Clin Oncol . 2005;23:9208–9218
  72. Diehl V , Franklin J , Pfreundschuh M , Lathan P , Paulus U , Hasenclever D , et al.   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease . N Engl J Med . 2003;348:2386–2395
  73. Diehl V , Schiller P , Engert A , Wolf J , Josting A , Mueller R , et al.   Results of the third interim analysis of the HD12 trial of the GHSG (eight courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin s Lymphoma) . Blood . 2003;102:85
  74. Straus DJ , Gaynor JJ , Myers J , Merke DP , Caravelli J , Chapman D , et al.   Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy . J Clin Oncol . 1990;8:1173–1186
  75. Federico M , Bellei M , Brice P , Brugiatelli M , Nagler A , Gisselbrecht C , et al.   High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy . J Clin Oncol . 2003;21:2320–2325
  76. Engert A , Ballova V , Haverkamp H , Pfistner B , Josting A , Duhmke E , et al.   Hodgkin’s lymphoma in elderly patients (a comprehensive retrospective analysis from the German Hodgkin’s Study Group) . J Clin Oncol . 2005;23:5052–5060
  77. Ballova V , Ruffer JU , Haverkamp H , Pfistner B , Muller-Hermelink HK , Duhmke E , et al.   A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) . Ann Oncol . 2005;16:124–131
  78. Aleman BM , Raemaekers JM , Tirelli U , Bortolus R , van ’t Veer MB , Lybeert ML , et al.   Involved-field radiotherapy for advanced Hodgkin’s lymphoma . N Engl J Med . 2003;348:2396–2406
  79. Loeffler M , Brosteanu O , Hasenclever D , Sextro M , Assouline D , Bartolucci AA , et al.  International Database on Hodgkin’s Disease Overview Study Group   Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease . J Clin Oncol . 1998;16:818–829
  80. Laskar S , Gupta T , Vimal S , Muckaden MA , Saikia TK , Pai SK , et al.   Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy (is there a need?) . J Clin Oncol . 2004;22:62–68
  81. Diehl V . Chemotherapy or combined modality treatment (the optimal treatment for Hodgkin’s disease) . J Clin Oncol . 2004;22:15–18
  82. Ferme C , Sebban C , Hennequin C , Divine M , Lederlin P , Gabarre J , et al.   Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease (results of the groupe d’etudes des lymphomes de l’Adulte H89 trial) . Blood . 2000;95:2246–2252
  83. Brice P , Colin P , Berger F , de Kerviler E , Divine M , Bouaffia F , et al.   Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy (a study of 82 patients from the Groupes d’Etudes des Lymphomes de l’Adulte H89 trial) . Cancer . 2001;92:453–459
  84. Fabian CJ , Mansfield CM , Dahlberg S , Jones SE , Miller TP , Van Slyck E , et al.   Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study . Ann Intern Med . 1994;120:903–912
  85. Horning SJ , Williams J , Bartlett NL , Bennett JM , Hoppe RT , Neuberg D , et al.   Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease (Eastern Cooperative Oncology Group Pilot Study E1492) . J Clin Oncol . 2000;18:972–980
  86. Josting A , Franklin J , May M , Koch P , Beykirch MK , Heinz J , et al.   New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group . J Clin Oncol . 2002;20:221–230
  87. Josting A , Rueffer U , Franklin J , Sieber M , Diehl V , Engert A . Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma (a report from the German Hodgkin Lymphoma Study Group) . Blood . 2000;96:1280–1286
  88. Lancet JE , Rapoport AP , Brasacchio R , Eberly S , Raubertas RF , Linder T , et al.   Autotransplantation for relapsed or refractory Hodgkin’s disease (long-term follow-up and analysis of prognostic factors) . Bone Marrow Transplant . 1998;22:265–271
  89. Crump M , Smith AM , Brandwein J , Coutere F , Sherret H , Sutton DMC , et al.   High-dose Etoposide and Melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease (Importance of disease status at transplant) . J Clin Oncol . 1993;11:704–711
  90. Moskowitz CH , Kewalramani T , Nimer SD , Gonzalez M , Zelenetz AD , Yahalom J . Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease . Br J Haematol . 2004;124:645–652
  91. Lazarus HM , Rowlings PA , Zhang MJ , Vose JM , Armitage JO , Bierman PJ , et al.   Autotransplants for Hodgkin’s disease in patients never achieving remission (a report from the Autologous Blood and Marrow Transplant Registry) . J Clin Oncol . 1999;17:534–545
  92. Constans M , Sureda A , Terol MJ , Arranz R , Caballero MD , Iriondo A , et al.   Autologous stem cell transplantation for primary refractory Hodgkin’s disease (results and clinical variables affecting outcome) . Ann Oncol . 2003;14:745–751
  93. Bonfante V , Santoro A , Viviani S , Devizzi L , Balzarotti M , Soncini F , et al.   Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD . J Clin Oncol . 1997;15:528–534
  94. Andre M , Henry-Amar M , Pico JL , Brice P , Blaise D , Kuentz M , et al.  Societe Francaise de Greffe de Moelle   Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure (a case-control study) . J Clin Oncol . 1999;17:222–229
  95. Linch DC , Winfield D , Goldstone AH , Moir D , Hancock B , McMillan A , et al.   Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease (results of a BNLI randomised trial) . Lancet . 1993;341:1051–1054
  96. Schmitz N , Pfistner B , Sextro M , Sieber M , Carella AM , Hanel M , et al.   Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease (a randomised trial) . Lancet . 2002;359:2065–2071
  97. Sureda A , Constans M , Iriondo A , Arranz R , Caballero VD , Vidal MJ , et al.   Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse . Ann Oncol . 2005;16:625–633
  98. Moskowitz CH , Nimer SD , Zelenetz AD , Trippett T , Hedrick EE , Filippa DA , et al.   A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease (analysis by intent to treat and development of a prognostic model) . Blood . 2001;97:616–623
  99. Josting A , Rudolph C , Reiser M , Mapara M , Sieber M , Kirchner HH , et al.   Time-intensified dexamethasone/cisplatin/cytarabine (an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease) . Ann Oncol . 2002;13:1628–1635
  100. Josting A , Rudolph C , Mapara M , Glossmann JP , Sienawski M , Sieber M , et al.   Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma (results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)) . Ann Oncol . 2005;16:116–123
  101. Santoro A , Bredenfeld H , Devizzi L , Tesch H , Bonfante V , Viviani S , et al.   Gemcitabine in the treatment of refractory Hodgkin’s disease (results of a multicenter phase II study) . J Clin Oncol . 2000;18:2615–2619
  102. Zinzani PL , Bendandi M , Stefoni V , Albertini P , Gherlinzoni F , Tani M , et al.   Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients . Haematologica . 2000;85:926–929
  103. Bergman AM , Ruiz van Haperen VW , Veerman G , Kuiper CM , Peters GJ . Synergistic interaction between cisplatin and gemcitabine in vitro . Clin Cancer Res . 1996;2:521–530
  104. Baetz T , Belch A , Couban S , Imrie K , Yau J , Myers R , et al.   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease (a phase II study by the National Cancer Institute of Canada Clinical Trials Group) . Ann Oncol . 2003;14:1762–1767
  105. Kuruvilla J , Nagy T , Pintilie M , Tsang R , Keating A , Crump M . Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma . Cancer . 2006;106:353–360
  106. Mundt AJ , Sibley G , Williams S , Hallahan D , Nautiyel J , Weichselbaum RR . Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease . Int J Radiat Oncol Biol Phys . 1995;33:261–270
  107. Pezner RD , Lipsett JA , Vora N , Forman SJ . Radical radiotherapy as salvage treatment for relapse of Hodgkin’s disease initially treated by chemotherapy alone (prognostic significance of the disease-free interval) . Int J Radiat Oncol Biol Phys . 1994;30:965–970
  108. Wirth A , Corry J , Laidlaw C , Matthews J , Liew KH . Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure . Int J Radiat Oncol Biol Phys . 1997;39:599–607
  109. Josting A , Nogova L , Franklin J , Glossmann JP , Eich HT , Sieber M , et al.   Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma (a retrospective analysis from the German Hodgkin Lymphoma Study Group) . J Clin Oncol . 2005;23:1522–1529
  110. Campbell B , Wirth A , Milner A , Di Iulio J , MacManus M , Ryan G . Long-term follow-up of salvage radiotherapy in Hodgkin’s lymphoma after chemotherapy failure . Int J Radiat Oncol Biol Phys . 2005;63:1538–1545
  111. O’Brien PC , Parnis FX . Salvage radiotherapy following chemotherapy failure in Hodgkin’s disease (what is its role?) . Acta Oncol . 1995;34:99–104
  112. Yahalom J . Integrating radiotherapy into bone marrow transplantation programs for Hodgkin’s disease . Int J Radiat Oncol Biol Phys . 1995;33:525–528
  113. Yahalom J , Gulati SC , Toia M , Maslak P , McCarron EG , O’Brien JP , et al.   Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease . J Clin Oncol . 1993;11:1062–1070
  114. Tsang RW , Gospodarowicz MK , Sutcliffe SB , Crump M , Keating A  PMH Lymphoma Group  Toronto Autologous BMT Group . Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin’s disease . Eur J Cancer . 1999;35:73–78
  115. Poen JC , Hoppe RT , Horning SJ . High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease (The impact of involved field radiotherapy on patterns of failure and survival) . Int J Radiat Oncol Biol Phys . 1996;36:3–12
  116. Rapoport AP , Meisenberg B , Sarkodee-Adoo C , Fassas A , Frankel SR , Mookerjee B , et al.   Autotransplantation for advanced lymphoma and Hodgkin’s disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy . Bone Marrow Transplant . 2002;29:303–312
  117. Dawson LA , Saito NG , Ratanatharathorn V , Uberti JP , Adams PT , Ayash LJ , et al.   Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin’s disease . Int J Radiat Oncol Biol Phys . 2004;59:208–218
  118. Wadhwa P , Shina DC , Schenkein D , Lazarus HM . Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation? . Bone Marrow Transplant . 2002;29:183–189
  119. Wirth A , Prince HM , Wolf M , Stone JM , Matthews J , Gibson J , et al.   Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas (a prospective Australasian Leukaemia and Lymphoma Group Study) . Bone Marrow Transplant . 2005;35:291–298
  120. Bolwell BJ , Kalaycio M , Goormastic M , Dannley R , Andresen SW , Lichtin A , et al.   Progressive disease after ABMT for Hodgkin’s disease . Bone Marrow Transplant . 1997;20:761–765
  121. Mundt AJ , Connell PP , Mansur DB . What is the optimal treatment volume in Hodgkin’s disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy? . Radiat Oncol Investig . 1999;7:353–359
  122. Hodgson DC , Zhang-Salomons J , Rothwell D , Paszat LF , Tsang RW , Crump M , et al.   Evolution of treatment for Hodgkin’s disease (a population-based study of radiation therapy use and outcome) . Clin Oncol (R Coll Radiol) . 2003;15:255–263
  123. Aleman BM , van den Belt-Dusebout AW , Klokman WJ , Van’t Veer MB , Bartelink H , van Leeuwen FE . Long-term cause-specific mortality of patients treated for Hodgkin’s disease . J Clin Oncol . 2003;21:3431–3439
  124. Travis LB , Hill D , Dores GM , Gospodarowicz M , van Leeuwen FE , Holowaty E , et al.   Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma . J Natl Cancer Inst . 2005;97:1428–1437
  125. Travis LB , Gospodarowicz M , Curtis RE , Clarke EA , Andersson M , Glimelius B , et al.   Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease . J Natl Cancer Inst . 2002;94:182–192
  126. Glanzmann C , Kaufmann P , Jenni R , et al.   Cardiac risk after mediastinal irradiation for Hodgkin’s disease . Radiother Oncol . 1998;46:51–62
  127. Boivin JF , Hutchison GB , Lubin JH , Mauch P . Coronary artery disease mortality in patients treated for Hodgkin’s disease . Cancer . 1992;69:1241–1247
  128. Hancock SL , Hoppe RT . Long-term complications of treatment and causes of mortality after Hodgkin’s disease . Semin Radiat Oncol . 1996;6:225–242
  129. Hancock SL , Tucker MA , Hoppe RT . Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease . J Am Med Assoc . 1993;270:1949–1955
  130. King V , Constine LS , Clark D , Schwartz RG , Muhs AG , Henzler M , et al.   Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease . Int J Radiat Oncol Biol Phys . 1996;36:881–889
  131. Hull MC , Morris CG , Pepine CJ , Mendenhall NP . Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy . J Am Med Assoc . 2003;290:2831–2837
  132. Chronowski GM , Wilder RB , Tucker SL , Ha CS , Yoanes A , Fayad L , et al.   Analysis of in-field control and late toxicity for adults with early-stage Hodgkin’s disease treated with chemotherapy followed by radiotherapy . Int J Radiat Oncol Biol Phys . 2003;55:36–43
  133. Reinders JG , Heijmen BJ , Olofsen-van Acht MJ , van Putten WL , Levendag PC . Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up . Radiother Oncol . 1999;51:35–42
  134. Heidenreich PA , Hancock SL , Lee BK , Mariscal CS , Schnittger I . Asymptomatic cardiac disease following mediastinal irradiation . J Am Coll Cardiol . 2003;42:743–749
  135. Adams MJ , Lipsitz SR , Colan SD , Tarbell NJ , Treves ST , Diller L , et al.   Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy . J Clin Oncol . 2004;22:3139–3148
  136. Zinzani PL , Gherlinzoni F , Piovaccari G , Bendandi M , Ferretti RM , et al.   Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin’s disease patients . Haematologica . 1996;81:132–137
  137. Kulkarni SS , Sastry PS , Saikia TK , Parikh PM , Gopal R , Advani SH . Gonadal function following ABVD therapy for Hodgkin’s disease . Am J Clin Oncol . 1997;20:354–357
  138. Bonadonna G , Santoro A , Viviani S , Lombardi C , Ragni G . Gonadal damage in Hodgkin’s disease from cancer chemotherapeutic regimens . Arch Toxicol Suppl . 1984;7:140–145
  139. Behringer K , Breuer K , Reineke T , May M , Nogova L , Klimm B , et al.   Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy (a report from the German Hodgkin’s Lymphoma Study Group) . J Clin Oncol . 2005;23:7555–7564
  140. Kornblith AB , Anderson J , Cella DF , Tross S , Zuckerman E , Cherin E , et al.   Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD . Cancer . 1992;70:2508–2516
  141. Kornblith AB , Anderson J , Cella DF , Tross S , Zuckerman E , Cherin E , et al.  The Cancer and Leukemia Group B   Hodgkin disease survivors at increased risk for problems in psychosocial adaptation . Cancer . 1992;70:2214–2224
  142. Joly F , Henry-Amar M , Arveux P , Remen O , Tanguy A , Peny AM , et al.   Late psychosocial sequelae in Hodgkin’s disease survivors (a French population-based case-control study) . J Clin Oncol . 1996;14:2444–2453
  143. Loge JH , Abrahamsen AF , Ekeberg O , Kaasa S . Reduced health-related quality of life among Hodgkin’s disease survivors (a comparative study with general population norms) . Ann Oncol . 1999;10:71–77
  144. Greil R , Holzner B , Kemmler G , Kopp M , Buchowski A , Oberaigner W , et al.   Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin’s disease from 1969 to 1994 . Eur J Cancer . 1999;35:698–706
  145. Oldervoll LM , Kaasa S , Knobel H , Loge JH . Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors (results from a pilot study) . Eur J Cancer . 2003;39:57–63
  146. Cheson BD , Horning SJ , Coiffier B , Shipp MA , Fisher RI , Connors JM , et al.   Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas . J Clin Oncol . 1999;17:1244–1253
  147. Jerusalem G , Hustinx R , Beguin Y , Fillet G . Positron emission tomography imaging for lymphoma . Curr Opin Oncol . 2005;17:441–445
  148. Kazama T , Faria SC , Varavithya V , Phongkitkarun S , Ito H , Macapinlac HA . FDG PET in the evaluation of treatment for lymphoma (clinical usefulness and pitfalls) . Radiographics . 2005;25:191–207
  149. Castellucci P , Zinzani P , Nanni C , Farsad M , Moretti A , Alinari L , et al.   18F-FDG PET early after radiotherapy in lymphoma patients . Cancer Biother Radiopharm . 2004;19:606–612
  150. Rigacci L , Castagnoli A , Dini C , Carpaneto A , Matteini M , Alterini R , et al.   (18)FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin’s lymphoma (Long-term results) . Oncol Rep . 2005;14:1209–1214
  151. National Comprehensive Cancer Network (NCCN). The NCCN Clinical Practice Guidelines in Oncology. Hodgkin’s Disease. 2004. Available from: http://www.nccn.org.
  152. Radford JA , Eardley A , Woodman C , Crowther D . Follow up policy after treatment for Hodgkin’s disease (too many clinic visits and routine tests? A review of hospital records) . Br Med J . 1997;314:343–346
  153. Torrey MJ , Poen JC , Hoppe RT . Detection of relapse in early-stage Hodgkin’s disease (role of routine follow-up studies) . J Clin Oncol . 1997;15:1123–1130
  154. Dryver ET , Jernstrom H , Tompkins K , Buckstein R , Imrie KR . Follow-up of patients with Hodgkin’s disease following curative treatment (the routine CT scan is of little value) . Br J Cancer . 2003;89:482–486
  155. Jerusalem G , Beguin Y , Fassotte MF , Belhocine T , Hustinx R , Rigo P , et al.   Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease . Ann Oncol . 2003;14:123–130
  156. Hutchings M , Loft A , Hansen M , Pedersen LM , Buhl T , Jurlander J , et al.   FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma . Blood . 2006;107:52–59

PII: S0147-0272(06)00017-1

doi: 10.1016/j.currproblcancer.2006.04.001

Current Problems in Cancer
Volume 30, Issue 3 , Pages 107-158 , May 2006

Article Tools

* Image Usage & Resolution